Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
DCK	1633	ELACYTARABINE	CHEMBL2105665		DrugBank
DCK	1633	TETRAHYDROURIDINE	CHEMBL1236475		NCI	17296311
DCK	1633	CAMPTOTHECIN	CHEMBL65		NCI	14973057
DCK	1633	FLUDARABINE	CHEMBL1568		TdgClinicalTrial
DCK	1633	CLADRIBINE	CHEMBL1619		NCI	10606241, 18570408
DCK	1633	TEZACITABINE	CHEMBL2105467		NCI	10961690
DCK	1633	DEOXYCYTIDINE	CHEMBL66115		NCI, DrugBank	10471381, 11952160
DCK	1633	CHEMBL23094	CHEMBL23094		NCI	3262616

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
DCK	rs4643786	CC + CT	ara-CTP	metabolism/PK	yes		Genotypes CC + CT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype TT.	30088438	1449751996
DCK	rs3775289	CC	gemcitabine	efficacy	no	Response rate, median time to progression, and median survival time were not significantly different among patients with differing genotypes.	Genotype CC is not associated with increased response to gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CT + TT.	18538445	981785517
DCK	rs4694362	TT	gemcitabine	efficacy	no	Tumor response to therapy and progression free survival did not significantly differ between genotype groups.	Genotype TT is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	20665488	981793968
DCK	rs66878317	AG + GG	gemcitabine	metabolism/PK	yes	Intrinsic clearance, calculated as Vmax/Km, and indicated by a reduced Km. In vitro study using purified proteins. Clearance of gemcitabine into its monophosphorylated form.	Genotypes AG + GG are associated with increased clearance of gemcitabine as compared to genotype AA.	23230131	982047196
DCK	rs4694362	T	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele T is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele C.	24361227	1184086246
DCK	rs12648166	A	gemcitabine	"efficacy","toxicity"	no	SNPs were selected based on prior literature and no alleles demonstrated any association with neurotoxicity or overall survival.	Allele A is not associated with response to gemcitabine and paclitaxel in women with Breast Neoplasms as compared to allele G.	24361227	1184086242
DCK	rs12648166	AA	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups.	Genotype AA is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AG + GG.	20665488	981793982
DCK	rs80143932	G	cytarabine	efficacy	yes	Patients were divided into "good responders" and "poor responders" and frequencies of haplotypes were compared between groups. Good responders were those that went into complete remission with the first induction of AraC and idarubicin and remained relapse free for at least 6 months afterwards. Among the patients there were three compound haplotypes at rs80143932 and rs2306744: CC/CC, CG/CT, and GG/TT. Patients with the G/T haplotype were more likely to be good responders. Patients with the C/C haplotype were more likely to be poor responders. rs80143932 and rs2306744 SNPs were also reported to be in very high linkage disequilibrium.	Allele G is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	15564883	1184175118
DCK	rs2306744	T	cytarabine	efficacy	yes	Patients were divided into "good responders" and "poor responders" and frequencies of haplotypes at rs80143932 and rs2306744 were compared between groups. Good responders were those that went into complete remission with the first induction of AraC and idarubicin and remained relapse free for at least 6 months afterwards. Among the patients there were three compound haplotypes at rs80143932 and rs2306744: CC/CC, CG/CT, and GG/TT. Patients with the G/T haplotype were more likely to be good responders. Patients with the C/C haplotype were more likely to be poor responders. rs80143932 and rs2306744 SNPs were also reported to be in very high linkage disequilibrium.	Allele T is associated with increased response to cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C.	15564883	1184175124